

# Srinivasan Madhusudan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12049053/publications.pdf>

Version: 2024-02-01

38  
papers

6,544  
citations

293460

24  
h-index

406436

35  
g-index

38  
all docs

38  
docs citations

38  
times ranked

9308  
citing authors

#	ARTICLE	IF	CITATIONS
1	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. <i>Cancers</i> , 2019, 11, 1149.	1.7	9
2	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 11-25.	0.4	1
3	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018, 119, 27-35.	2.9	19
4	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (VIP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology</i> , 2017, 18, 486-499.	5.1	60
5	DNA damage repair in breast cancer and its therapeutic implications. <i>Pathology</i> , 2017, 49, 156-165.	0.3	47
6	Prognostic and Predictive Significance of Base Excision Repair in Human Cancers. , 2017, , 609-662.		0
7	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016, 114, 965-971.	2.9	39
8	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 967-978.	5.1	221
9	DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets. <i>Journal of Biomolecular Screening</i> , 2015, 20, 829-841.	2.6	16
10	Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 411-421.	1.1	27
11	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 829-840.	5.1	296
12	Dysregulation of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma. <i>British Journal of Ophthalmology</i> , 2014, 98, 402-407.	2.1	7
13	Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?. <i>Medical Oncology</i> , 2014, 31, 46.	1.2	4
14	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , 2014, 15, 78-86.	5.1	516
15	DNA repair in cancer: emerging targets for personalized therapy. <i>Cancer Management and Research</i> , 2014, 6, 77.	0.9	55
16	Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. <i>Oncotarget</i> , 2014, 5, 3273-3286.	0.8	47
17	Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. <i>Oncotarget</i> , 2014, 5, 5764-5781.	0.8	8
18	Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 515-527.	1.1	35

#	ARTICLE	IF	CITATIONS
19	Inflammatory oncotaxis in cholangiocarcinoma. <i>Grand Rounds</i> , 2013, 13, 57-62.	0.2	1
20	Targeting DNA base excision repair: a new strategy for personalised cancer therapy. <i>Clinical Medicine</i> , 2012, 12, s42-s46.	0.8	1
21	Personalized Cancer Medicine. , 2012, , 257-282.		2
22	Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. <i>BMC Cancer</i> , 2012, 12, 511.	1.1	23
23	Editorial [Hot Topic: Evolving Drug Targets in DNA Base Excision Repair for Cancer Therapy (Guest) Tj ETQq1 1 0.784314 rgBT <sub>3</sub> /Overlook	0.7	3
24	Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. <i>International Journal of Cancer</i> , 2012, 131, 2433-2444.	2.3	79
25	Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 425-435.	3.4	203
26	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	13.9	3,370
27	Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. <i>Cancer Treatment Reviews</i> , 2007, 33, 565-577.	3.4	153
28	Cancer Pharmacogenomics. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 361-380.	1.6	25
29	Tyrosine Kinase Inhibitors and Cancer Therapy. , 2007, 172, 25-44.		5
30	Isolation of a small molecule inhibitor of DNA base excision repair. <i>Nucleic Acids Research</i> , 2005, 33, 4711-4724.	6.5	206
31	Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5950-5959.	0.8	146
32	DNA repair inhibition: a selective tumour targeting strategy. <i>Trends in Molecular Medicine</i> , 2005, 11, 503-511.	3.5	96
33	The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 603-617.	3.4	206
34	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor $\alpha$ Inhibitor in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6528-6534.	3.2	180
35	A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. <i>Clinical Cancer Research</i> , 2004, 10, 2986-2996.	3.2	76
36	Tyrosine kinase inhibitors in cancer therapy. <i>Clinical Biochemistry</i> , 2004, 37, 618-635.	0.8	197

#	ARTICLE	IF	CITATIONS
37	Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. <i>Clinical Cancer Research</i> , 2003, 9, 1648-55.	3.2	98
38	Drug inhibition of angiogenesis. <i>Current Opinion in Pharmacology</i> , 2002, 2, 403-414.	1.7	67